High doses of deferiprone may be associated with cerebellar syndrome

BMJ (Online)

Volumn 338, Issue 7695, 2009, Pages

  Beau Salinas, F ^a   Guitteny, M A ^b   Donadieu, J ^c   Jonville Bera, A P ^a   Autret Leca, E ^d  

^a CHU BRETONNEAU   (France)

^b CENTRE HOSPITALIER RÉGIONAL D ORLÉANS   (France)

^c ARMAND TROUSSEAU HOSPITAL   (France)

^d UNIVERSITÉ DE TOURS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DEFERIPRONE;

ANAMNESIS; ARTICLE; BRAIN RADIOGRAPHY; CASE REPORT; CEREBELLUM DISEASE; CEREBROSPINAL FLUID; CHILD; CLINICAL FEATURE; DIPLOPIA; DIZZINESS; DRUG DOSE INCREASE; DRUG MEGADOSE; DRUG WITHDRAWAL; FEMALE; HUMAN; IRON OVERLOAD; MALE; MUSCLE HYPOTONIA; NUCLEAR MAGNETIC RESONANCE IMAGING; NYSTAGMUS; OBSESSIVE COMPULSIVE DISORDER; PRIORITY JOURNAL; SCHOOL CHILD; THALASSEMIA MAJOR;

BETA-THALASSEMIA; CEREBELLAR DISEASES; CHILD; FEMALE; HUMANS; IRON CHELATING AGENTS; IRON OVERLOAD; MALE; PYRIDONES;

EID: 84858997155     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bjm.a2319     Document Type: Article

References (3)

1. Fredenburg AM, Sehti RK, Allen DD, Yokel RA. The pharmacokinetics and blood-brain barrier permeation of the chelators 1,2 dimethyl-,1,2 diethyl-, and 1 -[ethan-1 'ol]-2-methyl-3-hydoxypyridin-4-one in the rat. Toxicology 1996;108:191 -9.[CrossRef][lSI][Medline]
2. Marciani MG, lani C, Desaito MT, Spanedda F, Bassetti MA, Cianciulli P. Subclinical auditory and visual involvement during oral deferiprone therapy. Am J Hematol 1996;51:179-80.[CrossRef][ISI][Medline]
3. Barman Balfour JA, Foster RH. Deferiprone: a review of its clinical potential in iron overload in beta- thalassemia major and other transfusion-dependent diseases. Drugs 1999:58:553-78[CrossRef][lSI] [Medline]